Tyler J. Cook

Tyler Cook advises clients on public and private mergers and acquisitions, registered and exempt securities offerings, corporate governance, board advisory and SEC reporting, disclosure, and compliance matters.

After graduating from the University of Pennsylvania Carey Law School, Tyler joined Cravath, Swaine & Moore LLP where he gained invaluable experience representing a wide array of clients on a variety of corporate transactions. Throughout his career, he has advised numerous clients on M&A transactions with an aggregate value of over $60 billion and has advised clients on dozens of private and public securities offerings that raised over $10 billion. 

Prior to attending law school, he taught middle school in Harlem, New York as part of Teach for America. Outside of the office, Tyler enjoys spending time with his family, playing tennis and pickleball, and traveling.

Recognition

• Best Lawyers: Ones to Watch^® in America
  
  • Securities/Capital Markets Law (2024-2027)
  • Securities Regulation (2024-2027)
• North Carolina Super Lawyers Rising Star (2026-2027)
• Senior Editor, University of Pennsylvania Law Review
• Coca-Cola Scholar

Education

• University of Pennsylvania Law School, J.D., magna cum laude, 2017
• Relay Graduate School of Education, M.A. in teaching, 2014
• University of North Carolina, B.A. with highest distinction in Political Science and Public Policy, 2012
  • Morehead-Cain Scholar
  • Phi Beta Kappa
  • Dean’s List

Bar & Court Admissions

• Leadership Triangle, Class 33 (2025)

• Represented a Nasdaq-listed bank holding company in its assumption of all customer deposits and certain other liabilities, and acquisition of substantially all loans and certain other assets, of a bridge bank, as successor to the failed bank subsidiary of a Nasdaq-listed bank holding company, from the Federal Deposit Insurance Corporation, as receiver for the bridge bank.
• Represented a Nasdaq-listed bank holding company in its acquisition of an NYSE-listed bank holding company for shares valued at approximately $5.3 billion.
• Represented a North Carolina mutual insurance holding company in its merger with a Minnesota mutual insurance holding company, combining two of the nation’s leading providers of medical professional liability insurance in the first-ever merger by a North Carolina-domiciled mutual insurance holding company, resulting in a combined company with over $2 billion in consolidated assets.
• Represented a publicly traded biotechnology company in its $140 million acquisition of a privately held, preclinical-stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases.
• Represented a private equity-owned, industry-leading contract development and manufacturing organization in its acquisition via tender offer of a Nasdaq-listed contract development and manufacturing organization, with a deal value of approximately $183 million.
• Represented a biotechnology company in its acquisition via merger of an early-stage company focused on developing manufactured kidney products, for a purchase price of approximately $50 million.
• Advised a contract research organization in a definitive agreement to acquire a specialized contract research organization for the biotechnology industry.
• Advised an online gaming company in a definitive agreement to acquire an online 3-D modeling company.
• Advised an online gaming company in an acquisition of a UK-based pioneer in the "kidtech" market.
• Represented a clinical-stage biopharmaceutical company in its proposed business combination with a special purpose acquisition company.
• Represented a Nasdaq-listed bank holding company in multiple capital markets transactions, including public offerings of senior notes, subordinated notes, and preferred stock, for aggregate proceeds exceeding $4.5 billion.
• Represented a state-chartered commercial bank in connection with the establishment and related offerings under a global bank note program generating more than $5 billion in proceeds.
• Represented a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism in its $93.4 million initial public offering on Nasdaq.
• Represented an NYSE-listed semiconductor manufacturing company in connection with establishing an at-the-market equity program for the offering and sale of up to $200 million of common stock.
• Represented a Nasdaq-listed pharmaceutical development company in connection with establishing an at-the-market equity program for the offering and sale of up to $50 million of common stock.
• Represented a Nasdaq-listed pharmaceutical development company in a $40 million public offering of common stock.
• Represented numerous start-up and emerging companies on convertible note financings, series seed preferred stock financings, and other private placements of securities.
• Advised numerous NYSE- and Nasdaq-listed public companies in various industries with respect to public disclosure and securities law compliance matters, NYSE and Nasdaq listing requirements, corporate governance, and general corporate matters.